Ophthalmic Surg Lasers Imaging Retina. 2021 Nov;52(11):578-585. doi: 10.3928/23258160-20211018-01. Epub 2021 Nov 1.
Although people of low socioeconomic status (SES) and certain racial groups are at greater risk of developing diabetic macular edema (DME), the extent these high-risk groups experience treatment differences is unknown. This study characterizes anti-vascular endothelial growth factor (anti-VEGF) injection use for DME.
Data were collected from an electronic health record at the Cole Eye Institute, Cleveland Clinic Foundation for patients who received anti-VEGF treatment for DME between 2012 and 2019 ( = 500).
White patients on average received more injections over a 1-year period than Black patients (4.93 ± 3.14 vs 3.20 ± 2.43; < .0001) and had fewer no-show appointments (1.39 ± 2.08 vs 3.23 ± 3.39; < .0001). There is an association between living in communities with lower average incomes and receiving fewer anti-VEGF injections (3.06 ± 2.70 vs 4.88 ± 3.19; = .005).
DME treatment differs based on race and SES. Racial and SES associations with anti-VEGF injections present potential obstacles for delivering optimal ophthalmic care. .
尽管社会经济地位较低（SES）和某些种族群体的人患糖尿病性黄斑水肿（DME）的风险更高，但这些高风险群体经历治疗差异的程度尚不清楚。本研究描述了抗血管内皮生长因子（anti-VEGF）注射治疗 DME 的情况。
该研究的数据来自克利夫兰诊所眼研究所的电子健康记录，共纳入 2012 年至 2019 年间接受 anti-VEGF 治疗 DME 的 500 例患者。
与黑人患者相比，白人患者在一年内平均接受的注射次数更多（4.93 ± 3.14 次比 3.20 ± 2.43 次；<.0001），且失约次数更少（1.39 ± 2.08 次比 3.23 ± 3.39 次；<.0001）。收入较低的社区居住与接受的 anti-VEGF 注射次数较少之间存在关联（3.06 ± 2.70 次比 4.88 ± 3.19 次； =.005）。
DME 的治疗因种族和 SES 而异。抗 VEGF 注射的种族和 SES 相关性为提供最佳眼科护理带来了潜在的障碍。
